Novel antifungal antibiotic BMY-28567. Structural study and biological activities.
Novel antifungal antibiotic BMY-28567. Structural study and biological activities.
复制标题
DOI：
10.1111/j.1749-6632.1988.tb40402.x
复制
发表时间：
1988-01-01
影响因子：
5.2
通讯作者：
Kawaguchi, H
中科院分区：
文献类型：
--
作者：
Oki, T;Saitoh, K;Kawaguchi, H
BMY-28567，由Actinomadura hibiscastr. P157-2（ATCC 53557）对多种真菌和酵母菌（包括临床上重要的病原体）的体外活性显著高于酮康唑或制霉菌素。对其他抗真菌药物没有交叉耐药性，该化合物抑制念珠菌、曲霉、小孢子菌、青霉和孢子丝菌属的5-氟胞嘧啶[flucytosine]-和阿替霉素B耐药菌株。BMY-28567对C.白念珠菌和新生隐球菌通过单次静脉给药或每日两次肌肉注射给药2 d。
BMY-28567, produced byActinomadura hibiscastr. no. P157-2 (ATCC 53557), was significantly more activein vitrothan either ketoconazole or nystatin against a wide variety of fungi and yeasts, including clinically important pathogens. There was no cross-resistance to other antifungal agents, and the compound inhibited 5-fluorocytosine [flucytosine]- and amphotericin B-resistant isolates ofCandida, Aspergillus, Microsporum, PenicilliumandSporothrixsp. BMY-28567 was highly effective against systemic infections withC. albicansandCryptococcus neoformansby a single intravenous dosing or by twice-daily intramuscular administration for 2 d in normal and immunosuppressed mice.